The Role of Diaphragmatic Surgery During Interval Debulking After Neoadjuvant Chemotherapy An Analysis of 74 Patients With Advanced Epithelial Ovarian Cancer

被引:9
|
作者
Tsolakidis, Dimitris [1 ]
Amant, Frederic [1 ]
Van Gorp, Toon [1 ]
Leunen, Karin [1 ]
Neven, Patrick [1 ]
Vergote, Ignace [1 ]
机构
[1] Katholieke Univ Leuven, Div Gynecol Oncol, Dept Obstet & Gynaecol, Univ Hosp Leuven, B-3000 Louvain, Belgium
关键词
Interval debulking; Diaphragmatic surgery; Coagulation; Stripping; Advanced ovarian cancer; ADVANCED OVARIAN-CANCER; CARCINOMA; MANAGEMENT; PROGNOSIS; RESECTION; SURVIVAL;
D O I
10.1111/IGC.0b013e3181d4de23
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objectives: The purpose of this retrospective study was to evaluate diaphragmatic surgery in achieving optimal cytoreductive results and its associated complications during interval debulking surgery in patients with advanced ovarian cancer. Methods: After retrospective review of medical records, diaphragmatic surgery was performed in 74 of 128 consecutive patients with advanced epithelial ovarian cancer who underwent interval debulking, between September 1993 and December 2007. Four different approaches were performed: coagulation (group 1), stripping (group 2), combination of stripping with coagulation (group 3), and diaphragm full-thickness resection including muscle with pleura (group 4). Cytoreductive outcome, morbidity, overall survival, and disease-free survival were analyzed. Results: Two patients (2.7%) had International Federation of Gynecology and Obstetrics stage IIIB disease; 46 (62.16%), stage IIIC; and 26 (35.13%), stage IV. After 3 to 4 cycles of neoadjuvant platinum-based chemotherapy, the diaphragmatic disease was coagulated in 43 patients (58.10%) and was only stripped in 10 (13.51%); in 19 patients (25.67%), a combination of these techniques was applied; and in 2 (2.70%), the disease was resected, with the adjacent infiltrated part of the diaphragmatic muscle and the pleura above it. Debulking to no residual was achieved in 95%, 100%, 100%, and 50% for groups 1, 2, 3, and 4, respectively. The median disease-free survival was 15, 14, and 14 months, and the median overall survival was 34, 30, and 51 months for groups 1, 2, and 3, respectively, and were not reached for group 4. Minor and major complications were comparable among the groups. Pleural effusions were the most frequent associated complication, and chest tube placement (1.3%) or thoracocentesis (4%) were necessary for the relief of respiratory distress. The perioperative mortality rate was 0%. Conclusions: Diaphragmatic surgery during interval debulking enhances optimal cytoreduction rates and improves survival with acceptable and manageable morbidity. In patients with thick (94 mm) or large (91 cm) lesions, stripping the diaphragm or full-thickness resection of the diaphragmatic muscle is preferred.
引用
收藏
页码:542 / 551
页数:10
相关论文
共 50 条
  • [41] Timing of interval debulking surgery and postoperative chemotherapy after neoadjuvant chemotherapy in advanced epithelial ovarian cancer: a multicenter real-world study
    Liu, Xingyu
    Zhao, Yingjun
    Jiao, Xiaofei
    Yu, Yang
    Li, Ruyuan
    Zeng, Shaoqing
    Chi, Jianhua
    Ma, Guanchen
    Huo, Yabing
    Li, Ming
    Peng, Zikun
    Liu, Jiahao
    Zhou, Qi
    Zou, Dongling
    Wang, Li
    Li, Qingshui
    Wang, Jing
    Yao, Shuzhong
    Chen, Youguo
    Ma, Ding
    Hu, Ting
    Gao, Qinglei
    JOURNAL OF OVARIAN RESEARCH, 2023, 16 (01)
  • [42] Timing of interval debulking surgery and postoperative chemotherapy after neoadjuvant chemotherapy in advanced epithelial ovarian cancer: a multicenter real-world study
    Xingyu Liu
    Yingjun Zhao
    Xiaofei Jiao
    Yang Yu
    Ruyuan Li
    Shaoqing Zeng
    Jianhua Chi
    Guanchen Ma
    Yabing Huo
    Ming Li
    Zikun Peng
    Jiahao Liu
    Qi Zhou
    Dongling Zou
    Li Wang
    Qingshui Li
    Jing Wang
    Shuzhong Yao
    Youguo Chen
    Ding Ma
    Ting Hu
    Qinglei Gao
    Journal of Ovarian Research, 16
  • [43] The Effect of the Interval from the Third Cycle of Neoadjuvant Chemotherapy to Interval Debulking Surgery on the Surgical Results in Advanced Epithelial Ovarian Cancer
    Mahmoud Hanafy Meleis
    Ahmed Mohammed Samy El-Agwany
    Indian Journal of Gynecologic Oncology, 2016, 14 (1)
  • [44] The Effect of the Interval from the Third Cycle of Neoadjuvant Chemotherapy to Interval Debulking Surgery on the Surgical Results in Advanced Epithelial Ovarian Cancer
    Meleis, Mahmoud Hanafy
    El-Agwany, Ahmed Mohammed Samy
    INDIAN JOURNAL OF GYNECOLOGIC ONCOLOGY, 2016, 14 (01)
  • [45] Laparoscopic Debulking Surgery in the Management of Advanced Ovarian Cancer After Neoadjuvant Chemotherapy
    Corrado, Giacomo
    Mancini, Emanuela
    Cutillo, Giuseppe
    Baiocco, Ermelinda
    Vici, Patrizia
    Sergi, Domenico
    Patrizi, Lodovico
    Saltari, Maria
    Baffa, Alberto
    Vizza, Enrico
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2015, 25 (07) : 1253 - 1257
  • [46] The role of minimally invasive interval debulking surgery in advanced epithelial ovarian cancer
    Menderes, Gulden
    Black, Jonathan D.
    Azodi, Masoud
    EXPERT REVIEW OF ANTICANCER THERAPY, 2016, 16 (09) : 899 - 901
  • [47] Impact of delay in interval debulking surgery after neoadjuvant chemotherapy on survival in ovarian cancer
    Khalil, Kheyal Azam
    Habib, Maria
    Saeed, Afshan
    Syed, Aamir Ali
    Anwer, Abdul Wahid
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2024, 34 (SUPPL_1) : A284 - A285
  • [48] Safety and efficacy of neoadjuvant chemotherapy containing bevacizumab and interval debulking surgery for advanced epithelial ovarian cancer: A feasibility study
    Komiyama, Shinichi
    Kugimiya, Tsuyoki
    Kubushiro, Kaneyuki
    JOURNAL OF SURGICAL ONCOLOGY, 2018, 118 (04) : 687 - 693
  • [49] Neoadjuvant Chemotherapy Followed by Interval Debulking Surgery and the Risk of Platinum Resistance in Epithelial Ovarian Cancer
    Alexandre A. B. A. da Costa
    Camila V. Valadares
    Glauco Baiocchi
    Henrique Mantoan
    Augusto Saito
    Solange Sanches
    Andréia P. Guimarães
    Maria Isabel W. Achatz
    Annals of Surgical Oncology, 2015, 22 : 971 - 978
  • [50] Neoadjuvant Chemotherapy Followed by Interval Debulking Surgery and the Risk of Platinum Resistance in Epithelial Ovarian Cancer
    da Costa, Alexandre A. B. A.
    Valadares, Camila V.
    Baiocchi, Glauco
    Mantoan, Henrique
    Saito, Augusto
    Sanches, Solange
    Guimaraes, Andreia P.
    Achatz, Maria Isabel W.
    ANNALS OF SURGICAL ONCOLOGY, 2015, 22 : S971 - S978